Rilzabrutinib therapy in pemphigus patients shows effective outcomes in phase 2 trial Jacinthlyn Sylvia11 April 2024 8:00 AM ISTA recent phase 2 clinical trial found positive outcomes in patients with pemphigus a rare and potentially life-threatening autoimmune disease. The...
Trial Reveals Long-Term Success of First-Line Rituximab Treatment for Pemphigus Patients Dr.Niharika Harsha B25 March 2024 7:00 PM ISTIn a revolutionary development for pemphigus treatment, a 7-year follow-up study of the Ritux 3 trial has unveiled the remarkable long-term efficacy...
Ofatumumab subcutaneous injection promising treatment option for refractory pemphigus vulgaris: Study Medha Baranwal4 March 2024 2:00 AM ISTChina: A recent study published in The Journal of Dermatology has suggested ofatumumab to be a promising treatment option for patients with refractory...
Study finds high incidence of bullous pemphigoid in patients undergoing chronic dialysis Medha Baranwal3 Nov 2023 10:00 PM ISTTaiwan: A recent study published in The Journal of Dermatology has revealed chronic dialysis to be an independent risk factor for the development of...
Pemphigus closely associated with increased prevalence and severity of mood disorders Jacinthlyn Sylvia9 July 2023 11:30 PM ISTA recent study found the increased psychological impact and mood disorders associated to pemphigus, an autoimmune bullous disease. The findings were...
Presence of ARAs no contraindication to reinfusion of rituximab in pemphigus patients: JAMA Medha Baranwal19 Dec 2022 8:00 PM ISTFrance: Antirituximab antibodies (ARAs) are frequently detected in pemphigus patients treated with rituximab (RTX) and do not influence patients'...
Superficial radiotherapy gives long-term improvement in familial benign chronic pemphigus: JAMA Medical Dialogues Editorial Team14 Jan 2022 8:15 AM ISTDenmark: A new study discovered that superficial radiation (SR) treatment was related to remission in individuals with severe Hailey-Hailey disease...
Sanofi Rilzabrutinib phase 3 trial for Pemphigus treatment fails to meet endpoints Ruchika Sharma11 Sept 2021 4:08 PM ISTParis: In a setback to Sanofi, the Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet...
Female pemphigus patients at an increased risk of developing RA, Finds study Dr. Nandita Mohan1 Dec 2020 10:15 PM ISTResearchers have demonstrated an increased risk of developing RA among female pemphigus patients, according to a recent study published in the...
Sanofi to acquire US-based Principia for USD 3.7 billion Ruchika Sharma18 Aug 2020 1:09 PM ISTThe acquisition, announced by Sanofi and Principia gives Principia's pipeline in autoimmune diseases. They include a drug aimed at the rare but...
